Traws Pharma, Inc., incorporated in Delaware on December 22, 1998 and commenced operations on January 1, 1999, is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule drug candidates for the treatment of cancer. Traws is developing next-generation, best-in-class antiviral drugs for influenza, COVID and other respiratory infections, as well as narazaciclib for oncology. 

Traws Pharma shares fall 20.30% intraday as FDA places tivoxavir marboxil on clinical hold over mutagenicity concerns.

Traws Pharma shares fall -22.38% premarket after FDA places tivoxavir on clinical hold due to mutagenicity concerns.

Traws Pharma shares fall 22.34% after-hours as FDA places tivoxavir marboxil on clinical hold over mutagenicity concerns.

Traws Pharma shares fall 19.8% intraday as FDA places tivoxavir marboxil on clinical hold.

Traws Pharma shares fall 23.63% intraday as FDA places clinical hold on Tivoxavir Marboxil IND due to mutagenic data issues, delaying flu prevention project.

TRAW News